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Recent reports have illustrated a reciprocal relationship between circadian rhythm
disruption and mood disorders. The 5-HT7 receptor may provide a crucial link between the
two sides of this equation since the receptor plays a critical role in sleep, depression, and
circadian rhythm regulation. To further define the role of the 5-HT7 receptor as a potential
pharmacotherapy to correct circadian rhythm disruptions, the current study utilized the
selective 5-HT7 antagonist JNJ-18038683 (10 mg/kg) in three different circadian paradigms.
While JNJ-18038683 was ineffective at phase shifting the onset of wheel running activity
in mice when administered at different circadian time (CT) points across the circadian
cycle, pretreatment with JNJ-18038683 blocked non-photic phase advance (CT6) induced
by the 5-HT1A/7 receptor agonist 8-OH-DPAT (3 mg/kg). Since light induced phase shifts
in mammals are partially mediated via the modulation of the serotonergic system, we
determined if JNJ-18038683 altered phase shifts induced by a light pulse at times known
to phase delay (CT15) or advance (CT22) wheel running activity in free running mice. Light
exposure resulted in a robust shift in the onset of activity in vehicle treated animals at both
times tested. Administration of JNJ-18038683 significantly attenuated the light induced
phase delay and completely blocked the phase advance. The current study demonstrates
that pharmacological blockade of the 5-HT7 receptor by JNJ-18038683 blunts both non-
photic and photic phase shifts of circadian wheel running activity in mice. These findings
highlight the importance of the 5-HT7 receptor in modulating circadian rhythms. Due to
the opposite modulating effects of light resetting between diurnal and nocturnal species,
pharmacotherapy targeting the 5-HT7 receptor in conjunction with bright light therapy may
prove therapeutically beneficial by correcting the desynchronization of internal rhythms
observed in depressed individuals.
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INTRODUCTION
Circadian rhythms are governed by a variety of environmental
inputs including light, food, social interaction, and pharmaco-
logical agents (Lall et al., 2012; Bloch et al., 2013; Patton and
Mistlberger, 2013; Pendergast and Yamazaki, 2014). Of these,
light is the most powerful of the synchronizing agents (Klein
et al., 1991) and exerts its influence on circadian rhythms by
first exciting a subset of retinal ganglion cells that subsequently
activate neurons within the master circadian clock located in
the suprachiasmatic nucleus (SCN) via the retinohypothalamic
tract (RHT; Moore and Lenn, 1972; Gooley et al., 2001; Hattar
et al., 2002; Panda et al., 2002; Ruby et al., 2002). In addition
to photic input, serotoninergic pathways can also exert non-
photic influence over the synchronization of circadian rhythms
either by direct projections from raphe nucleus onto the SCN
or indirect via the intergeniculate leaflet onto the SCN (Moga
and Moore, 1997; Pickard and Rea, 1997; Ciarleglio et al., 2011).
Working in accordance with each other, the photic and non-
photic pathways help ensure proper synchronization of circadian
rhythms by responding to a variety of changes in the environ-
ment. Recent studies have demonstrated that the misalignment
or the inability to adjust to such derivations in the environ-
ment give rise to mood disorders in humans (Sprouse, 2004;
Grandin et al., 2006; Murray and Harvey, 2010; Salvadore et al.,
2010).
Utilizing a “clock in a dish” model, a role for the 5-HT7 recep-
tor in the modulation of the non-photic regulation of circadian
rhythms was noted for the first time when the receptor was ini-
tially cloned (Lovenberg et al., 1993). This method demonstrated
that the phase advance in neuronal activity of the SCN following
administration of the 5-HT1A/7 receptor agonist 8-OH-DPAT
was attenuated by the 5-HT7/2 receptor antagonist ritanserin, but
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not by pindolol, a 5-HT1A/1B receptor antagonist (Lovenberg
et al., 1993). This finding was later confirmed with the more
selective 5-HT7 receptor antagonist SB-269970 (Sprouse et al.,
2004). In vivo studies later reported the translational aspects of
this cell model by demonstrating that phase advances in wheel
running activity induced by 8-OH-DPAT were blocked following
the administration of the 5-HT7 receptor antagonist DR-4004
in hamsters and absent in the 5-HT7 receptor knockout (KO)
mouse (Ying and Rusak, 1997; Ehlen et al., 2001; Horikawa and
Shibata, 2004; Gardani and Biello, 2008; Horikawa et al., 2013).
In addition to its effects on the non-photic regulation of circadian
rhythms, there is evidence that the 5-HT7 receptor may also
influence photic regulation of circadian rhythms either by altering
the sensitivity to light or modulating the release of serotonin (Ying
and Rusak, 1997; Smith et al., 2001).
In addition to regulating circadian rhythms, the 5-HT7
receptor has been studied extensively for its role in depression.
Initial investigation noted that 5-HT7 receptor KO mice exhibited
an antidepressant-like phenotype in models of depression such
as the tail suspension and forced swim tests (Guscott et al.,
2005; Hedlund et al., 2005). Comparable antidepressant-like
effects were found in these behavioral tests with the selective 5-
HT7 receptor antagonist SB-269970 (Wesołowska et al., 2006;
Sarkisyan et al., 2010). While many studies have utilized SB-
269970 as a tool compound to investigate a role for the 5-HT7
receptor in various physiologic systems and pathological states,
its utility is hampered due to a short half-life and poor drug-
like properties (Hagan et al., 2000). Our in-house efforts yielded
JNJ-18038683, a selective 5-HT7 receptor antagonist that exhibits
better pharmacokinetic properties than SB-269970. Pre-clinical
and clinical evaluation of the compound demonstrated that
JNJ-18038683 was efficacious in the mouse tail suspension test
and also enhanced serotonin transmission, antidepressant-like
properties, and REM sleep suppression induced by the selective
serotonin reuptake inhibitor (SSRI) citalopram in rats (Bonaven-
ture et al., 2012). The effects of JNJ-18038683 on REM sleep trans-
lated from rodents to humans whereas the antidepressant efficacy
needed to be further assessed (Bonaventure et al., 2012). Inter-
estingly, systemic administration of the selective 5-HT7 receptor
agonist LP-211 significantly increased the time spent awake while
the direct infusion of this compound into dorsal raphe nucleus,
locus coeruleus, basal forebrain, or laterodorsal tegmental nucleus
resulted in decreased duration of REM sleep (Monti et al., 2008,
2014; Monti and Jantos, 2014). Similar REM sleep suppressive
effects were observed when another selective 5-HT7 receptor
agonist LP-44 was injected directly into the dorsal raphe nucleus
(Monti et al., 2008).
Given the association of the 5-HT7 receptor with mood and
circadian rhythms, pharmacological manipulation of this recep-
tor may provide a critical insight into the therapeutic link between
depression and circadian disruption. Therefore, the current study
was designed to examine a role for the 5-HT7 receptor in cir-
cadian rhythm regulation by administering the selective 5-HT7
receptor antagonist JNJ-18038683 in both photic and non-photic
circadian paradigms. To determine if JNJ-18038683 exerts direct
phase resetting properties, a phase response curve was gener-
ated by administering the compound to mice at select times
throughout the circadian cycle. Second, mice were administered
JNJ-18038683 to determine if the compound alters the non-
photic phase shift of wheel running activity induced by 8-OH-
DPAT. Finally, JNJ-18038683 was administered prior to a light
pulse that occurred at times known to delay (circadian time
(CT) 15) or advance (CT 22) the onset of wheel running activity
(Daan and Pittendrigh, 1976; Takahashi et al., 1984) in mice
to determine the effects of acute pharmacological blockade of
the 5-HT7 receptor on photic induced phase shifts. Results of
these studies demonstrate that the 5-HT7 receptor influences
both photic and non-photic aspects of circadian regulation and
therefore may provide a therapeutic avenue to alleviate circadian
disruptions associated with depression.
METHODS
ANIMALS
Studies conducted for the current investigation were performed
in accordance with the policies and regulations of the respec-
tive IACUC committees at Northwestern University and Janssen
Research and Development, L.L.C. For the experiments outlined
for the following studies, male C57Bl/6 J mice (average weight
∼30 grams) were purchased from Jackson Labs (Sacramento,
CA) and allowed to acclimate for at least 2 weeks before being
moved to environmental chambers that allowed for the abil-
ity to control lighting schedules and modified cages that con-
tained a running wheel. Mice were allowed access to food and
water ad libitum and maintained under a 12 h light/12 h dark
schedule.
DRUGS
JNJ-18038683 (1-Benzyl-3-(4-chlorophenyl)-1,4,5,6,7,8-hexahy
dropyrazolo[3,4-d]azepine) was synthesized by medicinal
chemistry group at Janssen Research and Development, L.L.C. as
the citrate salt form. For formulations, 20% (w/v) hydroxypropyl-
β-cyclodextrin was used to solubilize the compound and a
correction factor of 1.5690 was applied to compensate for the
salt form of JNJ-18038683. 8-OH-DPAT ((±)-8-Hydroxy-2-
dipropylaminotetralin hydrobromide) (Tocris Biosciences) was
formulated in saline. A correction factor of 1.32 was applied to
compensate for the hydrobromide salt form of 8-OH-DPAT. Both
compounds were injected in a volume of 10 mL/kg body mass.
With each compound, the pH of the solution was adjusted to
neutral before injection.
EXPERIMENTAL DESIGN
A phase response curve for JNJ-18038683 (10 mg/kg, i.p.) was
generated by administering the compound at various times across
the circadian cycle (CT2, 6, 10, 14, 18, or 22) to separate groups
of mice for each time point. For these studies, a single animal
was used in more than one injection condition and at least
2 weeks were given between conditions to prevent carry-over, or
interference effects from the previous trial.
To determine if JNJ-18038683 alters the phase advance of
wheel running activity induced by the 5-HT1A/7 receptor ago-
nist, 8-OH-DPAT, mice were first randomized into four separate
groups. Animals then received an injection of JNJ-18038683
(3 mg/kg, i.p.) or vehicle. Thirty minutes later, mice were further
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designated to receive 8-OH-DPAT (3 mg/kg, i.p.,) or correspond-
ing vehicle at CT6 which had been previously reported to result in
a phase advance of the onset of locomotor rhythm by 8-OH-DPAT
(Horikawa and Shibata, 2004).
To investigate the role of the 5-HT7 receptor on photic induced
phase shifts, JNJ-18036863 (10 mg/kg, s.c.) or vehicle was admin-
istered 30 min prior to an acute light pulse (200 lux, 30 min) that
occurred at times that are known to produce a photic phase delay
(CT 15) or advance (CT 22) of the onset of wheel running activity.
As a control for the light pulse, mice were placed in the chamber
but not exposed to light. For each treatment, separate groups of
mice were used.
WHEEL RUNNING ACTIVITY RECORDING AND ANALYSIS
Wheel running activity was recorded by a magnetic switch located
on the wheel that transferred each revolution as an event to an
IBM compatible computer in 5 min bins using ClockLab software.
Following at least a one-week acclimation period to adjust to the
running wheels and novel cage, mice were released into constant
darkness to assess free-running conditions and the onset of activ-
ity was monitored. On designated experimental days, the onset of
activity (designated by convention as CT 12) was calculated based
on the free running phase advance of activity of the previous 7
days. All timing for injections and light exposure was predicated
by the calculation of CT 12 for each animal. Wheel running
activity was monitored for at least 1 week following treatment
or corresponding control conditions for changes to the onset of
activity. A phase shift was calculated using ClockLab software and
defined as the difference in the onset of activity after treatment vs.
onset of activity prior to treatment. Data are expressed as mean
± S.E.M. To determine if JNJ-18038683 resulted in a significant
phase shift at various time points along the phase response curve,
an unpaired t-test (Vehicle vs. JNJ-18038683 treated animals) was
executed. A one factor, four-level ANOVA followed by post hoc
analysis was performed for each of the remaining two studies
to determine if the phase shift was significant with the four
treatment groups (p < 0.05). For visualization, a phase advance
is denoted as a positive value on the bar graph while a phase delay
is graphed as a negative value.
RESULTS
PHASE RESPONSE CURVE WITH JNJ-18038683
To determine the effects of the pharmacological blockade of the
5-HT7 receptor by JNJ-18038683 (10 mg/kg, i.p.), the compound
was administered at various circadian times throughout the sub-
jective circadian cycle (CT 2, 6, 10, 14, 18, 22) and the resulting
phase shift was calculated post administration and compared to
vehicle. At all times tested, JNJ-18038683 failed to elicit a phase
shift as determined by unpaired t-test (Table 1). In a separate
study, negative results were also obtained following the admin-
istration of a higher dose of JNJ-18038683 (20 mg/kg, i.p.) (data
not shown).
NON-PHOTIC REGULATION OF CIRCADIAN RHYTHMS BY THE 5-HT7
RECEPTOR
We then tested whether the 5-HT7 receptor antagonist JNJ-
18038683 would attenuate the phase advance of wheel running
Table 1 | Phase response curve following the administration of the
5-HT7 receptor antagonist JNJ-18038683 (10 mg/kg, i.p.) at various
circadian times.
Phase shift (min.)
CT Vehicle JNJ-18038683
2 0.0 ± 0.0 0.25 ± 0.25
6 0.0 ± 0.0 −0.15 ± 0.10
10 −0.20 ± 0.10 −0.29 ± 0.20
14 0.0 ± 0.0 −0.08 ± 0.08
18 0.0 ± 0.0 0.0 ± 0.0
22 0.0 ± 0.0 0.0 ± 0.0
FIGURE 1 | Phase shifting effects of JNJ-18038683 (3 mg/kg. i.p.) and
8-OH-DPAT (3 mg/kg, i.p.) on the circadian rhythms of wheel running
activity in mice. Mice were randomly divided to receive one of four
treatments: Vehicle + Vehicle (n = 14), Vehicle + 8-OH-DPAT (n = 21),
JNJ-18038683 + Vehicle (n = 11), and JNJ-18038683 + 8-OH-DPAT (n = 16).
After treatment, phase shifts of locomotor activity were calculated based
upon the onset of activity following treatment compared to prior treatment.
Results are expressed as mean ± S.E.M. and a one-way ANOVA followed
by a Tukey’s post hoc test was performed to determine if a result was
significant (****p < 0.0001 vs. Vehicle + Vehicle, JNJ-18038683 + Vehicle,
and JNJ-18038683 + 8-OH-DPAT).
locomotor activity elicited by the 5-HT1A/7 receptor agonist
8-OH-DPAT. Administration of the vehicle for JNJ-18038683
followed by 8-OH-DPAT resulted in a robust phase advance of
the onset of locomotor activity during constant dark conditions
(37.0 ± 6.3 min, F(3,58) = 18.49 p < 0.0001, one-way ANOVA,
Tukey’s post hoc analysis) when compared to the other three
treatment groups (Vehicle + Vehicle: −5.4 ± 4.1 min, JNJ-
18038683 + Vehicle −0.9 ± 3.6 min, JNJ-18038683 + 8-OH-
DPAT:−2.7± 3.0 min) (Figure 1). Comparable to what had been
measured during the generation of the phase response curve, the
administration of JNJ-18038683 in conjunction with the vehicle
for 8-OH-DPAT did not produce any phase shift at CT 6. The
administration of the 5-HT7 receptor antagonist JNJ-18038683
completely blocked the phase advance produced by 8-OH-DPAT
(Figure 1).
PHOTIC REGULATION OF CIRCADIAN RHYTHMS BY THE 5-HT7
RECEPTOR
To determine the effects of pharmacological blockade of
the 5-HT7 receptor on photic control of circadian rhythms,
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FIGURE 2 | The impact of the 5-HT7 receptor antagonist JNJ-18038683
(10 mg/kg, s.c.) on light induced phase shifts. Representative actigrams
and resulting phase shifts following administration of Vehicle/JNJ-18038683
or dark/light pulse on the circadian rhythms of wheel running activity in mice.
Mice were randomly divided to receive one of four treatments: Vehicle + Dark
(n = 5), Vehicle + Light Pulse (n = 6), JNJ-18038683 + Dark (n = 6), and
JNJ-18038683 + Light Pulse (n = 5, CT 15; n = 6, CT 22). The light pulse was
administered at times known to phase delay (CT15) (A,B) or advance (CT22)
(C,D) the onset of wheel running activity in mice. After treatment, phase
shifts of locomotor activity (onsets of activity indicated by bold black line)
were calculated based upon the onset of activity following treatment
compared to prior treatment. Results are expressed as mean ± S.E.M. and a
one-way ANOVA followed by a Tukey’s post hoc test was performed to
determine if a result was significant (Phase Delay—**p < 0.01 vs.
JNJ-18038683 + Light, ***p < 0.001 vs. JNJ-18038683 + Dark,
****p < 0.0001 vs. Vehicle + Dark and JNJ-18038683 + Dark; Phase
Advance—*p < 0.05 vs. JNJ-18038683 + Light, **p < 0.01 vs.
Vehicle + Dark and JNJ-18038683 + Dark).
JNJ-18038683 was administered prior to a light pulse and the
potential alterations in the onset of mouse wheel running activity
was analyzed. In vehicle treated animals, light exposure resulted in
a significant phase shift in the onset of activity at both times tested
(CT 15: −2.65 ± 0.12 h: F(3,18) = 42.37; CT22: 0.76 ± 0.19 h:
F(3,19) = 6.757 one way ANOVA, Tukey’s post hoc analysis)
(Figures 2A–D). Administration of JNJ-18038683 attenuated the
light-induced phase delay (−1.64± 0.29 h) (Figures 2C,D) while
the resulting phase advance following light exposure at CT 22 was
completely blocked by the compound (Figures 2A,B).
DISCUSSION
The present investigation examined the impact of the 5-HT7
receptor antagonist JNJ-18038683 on non-photic and photic
regulation of the circadian rhythm of wheel running activity in
mice. Results reported from these studies demonstrate that the
compound did not exert direct non-photic or photic phase reset-
ting properties by itself. However, JNJ-18038683 was able to block
the non-photic phase advance of wheel running activity induced
by the 5-HT1A/7 receptor agonist 8-OH-DPAT. In addition, JNJ-
18038683 completely blocked the phase advance and significantly
attenuated the phase delay of wheel running activity induced by a
light pulse.
PHASE RESPONSE CURVE OF JNJ-18038683
To determine if JNJ-18038683 exerts direct non-photic or photic
phase resetting effects in free running mice, the compound was
administered at specified times across the circadian cycle. At all
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times tested, JNJ-18038683 failed to elicit a phase shift when
compared to vehicle treated mice. The lack of effect with JNJ-
18038683 on phase shifts in mice was similar to what has been
reported for the 5-HT2/7 receptor antagonist, ritanserin and a
more selective 5-HT7 receptor antagonist SB-269970 in hamsters
and rats (Antle et al., 1998; Duncan et al., 2004; Westrich et al.,
2013). While antagonists for the 5-HT7 receptor do not modulate
non-photic regulation of circadian rhythms, agonists for this
receptor (8-OH-DPAT and LP-211) are capable of shifting the
onset of wheel running activity in constant conditions (Horikawa
and Shibata, 2004; Adriani et al., 2012). In addition, fluoxetine
that inhibits the reuptake of serotonin and therefore, universally
activates the serotonergic system has been shown to induce non-
photic phase shifts (Cuesta et al., 2008, 2009). Therefore, global
activation of the serotonergic system or direct pharmacological
activation of the 5-HT7 receptor may be needed to induce photic
or non-photic phase shifts.
NON-PHOTIC REGULATION OF CIRCADIAN RHYTHMS BY THE 5-HT7
RECEPTOR
The second study was designed to determine if the acute phar-
macological blockade of the 5-HT7 receptor with the selective
antagonist JNJ-18038683 impacted the phase advance of wheel
running activity induced by 8-OH-DPAT in mice. The timing
of 8-OH-DPAT administration was based on previous studies
that demonstrated a robust phase advance when the compound
was injected at CT 6 (Horikawa and Shibata, 2004). When JNJ-
18038683 was administered before 8-OH-DPAT in the current
study, the phase advance induced by the agonist was completely
blocked demonstrating the impact of the 5-HT7 receptor on
non-photic phase resetting of circadian rhythms. Since 8-OH-
DPAT is an agonist for both the 5-HT1 and 5-HT7 recep-
tors, future studies will utilize selective agonists for the 5-HT7
receptor (i.e., LP-44 or LP-211) to further elucidate the role
of the 5-HT7 receptor on non-photic regulation of circadian
rhythms.
Earlier in vivo and in vitro studies from other labs have
provided some insight into a mechanism by which the 5-HT7
receptor regulates non-photic control of circadian rhythms.
During mid-subjective day, micro-injection of 8-OH-DPAT or
5-Carboxamidotryptamine (5-CT) into the dorsal raphe nucleus
activates 5-HT7 receptors and subsequently phase advances the
circadian rhythms of wheel running activity in hamsters (Mintz
et al., 1997; Duncan et al., 2004; Duncan and Davis, 2005).
These phase shifts were blocked by the administration of the
selective 5-HT7 receptor antagonist SB-269970 (Duncan et al.,
2004). Further investigation delineated this model to show that
the activation of the 5-HT7 receptor inhibits glutamate release
within the dorsal raphe nucleus resulting in the inhibition of the
release of GABA from interneurons which subsequently relieves
the inhibition on serotonergic neurons located within the dor-
sal or medial raphe nucleus (Glass et al., 2003; Harsing et al.,
2004; Duncan and Congleton, 2010). The subsequent release of
serotonin onto the SCN results in non-photic phase modulation
(Duncan and Congleton, 2010). Therefore, administration of JNJ-
18038683 may be acting on 5-HT7 receptors within the dorsal
raphe nucleus to inhibit glutamate release and thus blocking
the non-photic phase shifts induced by 8-OH-DPAT. However,
further studies are needed to define specific pathways in which
the 5-HT7 receptor modulates non-photic circadian re-setting
since the receptor is localized not only within the dorsal/median
raphe nucleus to modulate GABA release, but also within the
primary circadian oscillator of the SCN and other brain regions
known to influence circadian rhythms such as the thalamus that
could potentially impact NPY release which has been shown
to alter non-photic phase shifts (Mrosovsky, 1996; Belenky and
Pickard, 2001; Neumaier et al., 2001; Bonaventure et al., 2002;
Gamble et al., 2006; Matthys et al., 2011; Hughes and Piggins,
2012).
PHOTIC REGULATION OF CIRCADIAN RHYTHMS BY THE 5-HT7
RECEPTOR
In addition to the non-photic influence of circadian rhythms,
serotonin can also alter photic responsiveness of the SCN pos-
sibly by acting via the 5-HT7 receptor. Early studies associated
the 5-HT7 receptor with changes in the sensitivity of light in
SCN neurons. Administration of serotonin, 5-CT, or 8-OH-DPAT
reduced the firing of SCN neurons located in the hamster fol-
lowing a light pulse (Ying and Rusak, 1997). This decrease in
neuronal firing was subsequently reversed by applying ritanserin
or clozapine which are known to antagonize the 5-HT7 receptor
but not the 5-HT1A/B/D receptor antagonist, cyanopindolol or
the 5-HT1A receptor antagonist WAY-100635 (Ying and Rusak,
1997). In subsequent studies, hypothalamic excitatory post synap-
tic currents evoked by optic nerve stimulation which mimics a
light pulse were reduced when the 5-HT1A/B agonist TFMPP
was added to the bath (Smith et al., 2001). The change in these
glutamate dependent currents within the hypothalamus were
significantly attenuated with ritanserin, thus further implicating
a role for the 5-HT7 receptor in photic control of circadian
rhythms by modulating glutamate transmission (Smith et al.,
2001). The additional findings that TFMPP had little effect in
this model in 5-HT1B receptor KO mice and was minimally
attenuated with the 5-HT1A receptor antagonist WAY-100635,
provide some indirect evidence that the role of the 5-HT7 receptor
in modulating photic control of circadian rhythms may be in
coordination with other serotonergic receptors and glutamatergic
neurotransmission.
Additional studies have investigated a role for the 5-HT7
receptor in the photic control of circadian rhythms by generat-
ing a phase response curve of light in 5-HT7 receptor KO and
corresponding WT mice (Gardani and Biello, 2008). Overall,
the phase shifts induced by the light pulse were comparable in
magnitude and direction between WT and 5-HT7 receptor KO
mice except at CT 22 (Gardani and Biello, 2008). At this time
point, the light pulse resulted in the requisite phase advance in
WT mice but a phase delay in the 5-HT7 receptor KO mice
(Gardani and Biello, 2008). Interestingly, while the current study
measured a significant attenuation of the light induced phase
delay at CT 15 with the administration of JNJ-18038683, there
was no difference in WT or 5-HT7 receptor KO mouse when
the light pulse was administered at CT 14 or 16 which replicated
an earlier report (Sprouse et al., 2003). The difference in regards
to the light induced phase shift at these earlier time points
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between the pharmacological and the genetic deletion of the
receptor may be the result of compensatory mechanisms involved
in the phase resetting after a light pulse at these earlier time
points of the subjective dark phase in the 5-HT7 receptor KO
mouse.
Since this is the first report of attenuation of phase shifts
following light pulses following the acute pharmacological block-
ade of the 5-HT7 receptor, additional studies are needed to
further investigate the mechanism by which the 5-HT7 recep-
tor is modulating the photic control of circadian rhythms.
Results from these studies will provide an explanation as to
why pharmacological blockade of the 5-HT7 receptor resulted in
diminished photic induced phase shifts as opposed to an enhance-
ment given the finding that activation of the 5-HT7 receptor
inhibits the RHT input to the SCN by decreasing glutamate
(Ying and Rusak, 1997; Smith et al., 2001). In addition, since
antagonists selective for the 5-HT7 receptor lack direct photic-
like phase shifting effects by themselves, the actions of these
5-HT7 receptor antagonists are probably due to the coordina-
tion with other serotonin receptors including the 5-HT1A and
5-HT1B receptors (Ying and Rusak, 1997; Rea, 1998; Smith et al.,
2001).
Similar to our findings that JNJ-18038683 diminished photic
induced phase resetting, pharmacological agents that are known
to activate the serotonin system such as SSRIs (fluoxetine, citalo-
pram, fluvoxamine, and paroxetine) also reduce the phase shift
induced by a light pulse in the hamster (Gannon and Millan,
2007). Interestingly, fluoxetine potentiates the light induced phase
shift in the diurnal species Arvicanthis ansorgei (Cuesta et al.,
2008). These contrasting effects between nocturnal and diurnal
species may be explained by the differential regulation of brain
concentrations of serotonin corresponding to arousal state and
also may be due to the changes in expression of circadian con-
trolled genes following a light pulse in nocturnal and diurnal
animals (Faradji et al., 1983; Poncet et al., 1993; Rea et al., 1994;
Weber et al., 1998; Cuesta et al., 2008). While the current study
did not measure the changes in the expression of such genes in
response to pharmacological manipulation of the 5-HT7 receptor,
Westrich and colleagues reported that the in vitro period as
measured by a luciferase reporter linked to the PER2 gene, can be
shortened by the 5-HT7 receptor agonist AS-19 and subsequently
blocked by the 5-HT7 receptor antagonist SB-269970 (Westrich
et al., 2013).
Due to the possible potentiation of the effects of light in
diurnal species such as humans, 5-HT7 receptor antagonists
may provide an interesting adjunctive therapy for the antide-
pressant effects associated with bright light therapy. The idea of
adjunctive therapy with a 5-HT7 receptor antagonist arose from
earlier studies in which JNJ-18038683 or SB-269970 enhanced
the antidepressant-like effects of an SSRI in pre-clinical stud-
ies (Bonaventure et al., 2007, 2012; Wesołowska et al., 2007).
When JNJ-18038683 was administered in combination with
citalopram, there was an enhancement of serotonin transmis-
sion, antidepressant-like behavior, and REM sleep suppression
induced by the SSRI in rodents (Bonaventure et al., 2012). In
another study, Westrich et al. demonstrated that the administra-
tion of escitalopram or the 5-HT7 receptor antagonist SB-269970
was ineffective at phase shifting wheel running activity in rats,
however, the co-administration of escitalopram with SB-269970
resulted in phase delays in rodent wheel running (Westrich
et al., 2013). In addition to adjunctive therapy with an SSRI,
a 5-HT7 receptor antagonist may also provide useful adjunc-
tive therapy to bright light exposure in humans. While bright
light therapy has been used for several decades as a stand-
alone antidepressant therapy for seasonal affective disorder (Pail
et al., 2011), it has also been used in conjunction with SSRI for
major depressive disorder to bolster and hasten the antidepressant
properties of SSRIs since the onset of mood improvement may
take several weeks and also to increase the responsiveness in
those individuals who are resistant to treatment with SSRIs by
themselves (Benedetti et al., 2003; Blier, 2003; Martiny, 2004;
Martiny et al., 2004; Wirz-Justice et al., 2005). There is clin-
ical evidence that bright light therapy with sertraline can be
therapeutically beneficial as an adjunct therapy for depression
resulting in significant reductions in the HAM-D scale of depres-
sion (Martiny et al., 2005a,b). In addition, combining bright
light therapy with citalopram has been shown to accelerate the
onset of the anti-depressant properties of the SSRI (Benedetti
et al., 2003). Therefore, combining bright light therapy with JNJ-
18038683 may enhance the antidepressant effects of the light
exposure in humans. Findings from these studies help provide
insight into the translational therapeutic benefits of combin-
ing a 5-HT7 receptor antagonist with additional antidepressant
modalities including bright light therapy that would correct the
various circadian disruptions that are commonly associated with
depression.
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